ARI-3037MO

Phase 2Small molecule

UUnknown Sponsor

ARI-3037MO is one of 57 small molecule programs targeting Hepatic steatosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic SteatosisActive, not recruiting

HypertriglyceridemiaActive, not recruiting

Hepatic SteatosisPhase 2

Active, not recruiting

HypertriglyceridemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Crestor

Lopid

Cipro

Selzentry

Lovaza

3 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Zetia

Statin

1 9

EVKEEZA

Regeneron

Phase 2

2 10

Ciprofibrate

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatic steatosis1 trial

A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis

Unknown status·UUnknown Sponsor·Phase 2·NCT02574325·11 enrolled

LDL-cholesterol1 trial

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Unknown status·UUnknown Sponsor·Phase 2·NCT02532218·176 enrolled

Hypertriglyceridemia1 trial

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

Completed·UUnknown Sponsor·Phase 2·NCT02250105·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARI-3037MO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARI-3037MO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARI-3037MO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUnknown Sponsor

ARI-3037MO

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatic steatosis1 trial

LDL-cholesterol1 trial

Hypertriglyceridemia1 trial

References

Drug Info

Quick Facts

Related News